Multihance (Gadobenate Dimeglumine)

Multihance (gadobenate dimeglumine) is employed as a gadolinium‑based contrast agent for magnetic resonance imaging procedures.

• Liver MRI: improves detection and characterization of focal hepatic lesions.
• Cardiovascular MRI: enhances visualization of myocardial perfusion and vascular anatomy.
• Central nervous system MRI: provides clearer delineation of brain tumors and inflammatory lesions.
• Magnetic resonance angiography (MRA): increases contrast of arterial and venous structures for detailed vascular assessment.

• Gadobenate dimeglumine is a chelated gadolinium complex that shortens the T1 relaxation time of nearby water protons. When administered intravenously, it distributes into the extracellular fluid and vascular space, producing a higher signal intensity on T1‑weighted MRI sequences, thereby improving the contrast between normal and pathological tissues.

Multihance may cause a range of adverse reactions following intravenous administration.

Common Side Effects

• Nausea: mild to moderate feeling of stomach upset.
• Headache: transient discomfort often reported during or after injection.
• Injection site discomfort: pain or burning sensation at the cannula site.
• Warmth sensation: brief feeling of heat spreading through the body.
• Dizziness: occasional light‑headedness shortly after dosing.

Serious or Rare Side Effects

• Severe allergic reaction or anaphylaxis: rapid onset of breathing difficulty, rash, or swelling.
• Nephrogenic systemic fibrosis (NSF): fibrotic skin changes in patients with severe renal impairment.
• Cardiovascular collapse: rare episodes of hypotension or cardiac arrest.
• Pulmonary edema: fluid accumulation in the lungs, observed in susceptible individuals.
• Renal failure exacerbation: worsening of pre‑existing kidney dysfunction.

Prior to using Multihance, clinicians should evaluate patient-specific risk factors and follow recommended handling procedures.

• Renal function assessment: verify glomerular filtration rate before administration.
• History of allergic reactions: screen for prior gadolinium or contrast agent hypersensitivity.
• Pregnancy considerations: use only if the diagnostic benefit outweighs potential fetal risk.
• Breastfeeding guidance: advise caution and consider temporary cessation of nursing.
• Severe renal impairment: avoid or use with extreme caution due to NSF risk.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Multihance can interact with other agents that affect renal function or gadolinium clearance.

Major Interactions (Avoid)

• Concurrent administration of other gadolinium‑based contrast agents: may increase cumulative gadolinium exposure and toxicity.
• High‑dose iron chelation therapy: can alter gadolinium binding and clearance.

Moderate Interactions (Monitor Closely)

• Nephrotoxic drugs (e.g., aminoglycosides, NSAIDs): monitor renal parameters closely.
• Diuretics: may affect fluid balance and gadolinium distribution.
• Beta‑blockers or antihypertensives: observe cardiovascular status during injection.
• Radiopharmaceuticals: coordinate timing to avoid overlapping contrast effects.